Sp473
AGA GUIDELINE: ENDOSCOPIC MANAGEMENT OF BARRETT'S ESOPHAGUS Q&A
Date
May 19, 2024
Presenters
Mayo Clinic
University of Colorado
Tracks
Related Products
A PROSPECTIVE, MULTI-INSTITUTIONAL STUDY REVEALS THE COMBINATION OF RNA ANALYSIS WITH DNA-BASED NEXT-GENERATION SEQUENCING (NGS) IMPROVES THE PREOPERATIVE CLASSIFICATION OF PANCREATIC CYSTS AND IDENTIFICATION OF ADVANCED NEOPLASIA
BACKGROUND: As outlined by the Kyoto guidelines, targeted DNA-based NGS of pancreatic cyst fluid (PCF) is an important adjunct to the evaluation of pancreatic cyst patients…
LOW INCIDENCE OF RECURRENT NEOPLASTIC BARRETT’S ESOPHAGUS (BE) AFTER SUCCESSFUL ENDOSCOPIC ERADICATION THERAPY (EET): LONG-TERM OUTCOMES FROM A MULTICENTER PROSPECTIVE COHORT STUDY
INTRODUCTION: EET is endorsed by guidelines for treatment of BE-related neoplasia patients. Few studies describe long-term durability outcomes in BE patients who achieve complete eradication of intestinal metaplasia (CE-IM) following EET…
Advances in Barrett's Esophagus
SOCIETY: AGA
COSTS ASSOCIATED WITH PANCREATIC CYST SURVEILLANCE DECREASED AFTER RISK-STRATIFICATION WITH NEXT-GENERATION SEQUENCING
Incidental detection of pancreatic cysts (PCs) is increasing and identifying high-risk cysts is of critical importance. Prior studies suggest significant cost associated with PC surveillance, which is more pronounced with over-management…
